Anson Funds Management LP Grows Holdings in NRx Pharmaceuticals, Inc. $NRXP

Key Points

• Anson Funds Management LP increased its stake in NRx Pharmaceuticals by 535.1%, acquiring 993,401 shares during the first quarter and now holds approximately 6.82% of the company.
• Several analysts have given NRx Pharmaceuticals a consensus rating of "Buy" with price targets ranging from $34.00 to $40.00, indicating positive sentiment towards the stock.
• NRx Pharmaceuticals recently reported a loss of ($0.98) earnings per share, which missed the consensus estimate, with predictions pointing towards a challenging fiscal year ahead.

Anson Funds Management LP lifted its holdings in shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Free Report) by 535.1% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,179,061 shares of the company's stock after purchasing an additional 993,401 shares during the quarter. Anson Funds Management LP owned about 6.82% of NRx Pharmaceuticals worth $2,417,000 as of its most recent filing with the SEC.

Separately, Squarepoint Ops LLC acquired a new stake in shares of NRx Pharmaceuticals during the fourth quarter worth about $56,000. Hedge funds and other institutional investors own 4.27% of the company's stock.

NRx Pharmaceuticals Price Performance

NASDAQ:NRXP traded up $0.10 on Tuesday, reaching $3.10. The stock had a trading volume of 122,328 shares, compared to its average volume of 504,688. The company has a market cap of $61.41 million, a price-to-earnings ratio of -1.38 and a beta of 1.63. The firm's fifty day moving average is $2.79 and its two-hundred day moving average is $2.56. NRx Pharmaceuticals, Inc. has a 12-month low of $1.10 and a 12-month high of $6.01.

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) last released its earnings results on Monday, August 18th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.67). As a group, research analysts forecast that NRx Pharmaceuticals, Inc. will post -1.75 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

NRXP has been the topic of several analyst reports. HC Wainwright initiated coverage on shares of NRx Pharmaceuticals in a report on Monday, September 8th. They issued a "buy" rating and a $40.00 target price on the stock. Wall Street Zen raised shares of NRx Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Zacks Research raised shares of NRx Pharmaceuticals to a "hold" rating in a report on Wednesday, September 10th. BTIG Research reissued a "buy" rating on shares of NRx Pharmaceuticals in a report on Monday, August 25th. Finally, D. Boral Capital reissued a "buy" rating and set a $34.00 price objective on shares of NRx Pharmaceuticals in a report on Monday, September 8th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, NRx Pharmaceuticals has an average rating of "Buy" and an average target price of $34.50.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.